希玛医疗控股有限公司（原名：希玛眼科医疗控股有限公司）是一家主要从事提供医疗服务业务的投资 控股公司。该公司通过四个部门运营业务。香港医疗业务分部主要从事在香港提供眼科、牙科及其他医 疗服务以及销售视力辅助产品业务。内地牙科业务分部主要从事在内地提供牙科服务业务。销售医疗耗 材分部主要从事在香港销售医疗耗材业务。内地眼科业务分部主要从事在内地提供眼科服务及销售视力 辅助产品业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月23日南向资金减持4.0万股希玛医疗（03309.HK）。近5个交易日中，获南向资金减 持的有5天，累计净减持44.2万股。近20个交易日中，获南向资金减持的有20天，累计净减持190.0万 股。截至目前，南向资金持有希玛医疗（03309.HK）7294.7万股，占公司已发行普通股的5.91%。 ...

Core Insights - The trend of foreign patients seeking medical treatment in China is gaining traction, particularly in areas such as dentistry, health check-ups, and traditional Chinese medicine, driven by visa-free policies and increased interest in medical services [1][3][4] Group 1: Market Dynamics - The demand for international medical services in China has surged, with a reported 1.28 million international patients treated in key hospitals in 2025, marking a 73.6% increase over three years, and a doubling of patients from Europe and the U.S. [4] - The efficiency, cost, and quality of medical services in China are key factors driving cross-border medical flows, attracting patients from both developing and developed countries [6][7] Group 2: Patient Experience - Chinese medical institutions are responding effectively to the needs of international patients, with services like same-day gastrointestinal examinations significantly reducing time costs [8] - Private hospitals in cities like Shanghai and Kunming have developed comprehensive capabilities to cater to cross-border patients, from diagnosis to rehabilitation [10] Group 3: Innovation and Drug Development - China's progress in drug development, particularly in innovative medications, is noteworthy, with the country becoming a new choice for global patients seeking advanced treatments [11][12] Group 4: Challenges and Opportunities - Despite the growth potential, China's inbound medical tourism remains in its infancy, with only an estimated 10,000 overseas patients expected in 2025 compared to over 1 million in Malaysia and South Korea [13] - Regulatory challenges, including the need for cross-border consensus on medical standards and payment systems, pose significant hurdles for the industry [16][18] Group 5: Future Outlook - The Shanghai region is actively promoting international medical tourism through pilot programs and policy initiatives, showing promising growth in patient numbers [15] - For sustainable growth in the inbound medical market, there is a need for improved integration of services and a more comprehensive approach to medical tourism [19]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Hema Medical (03309.HK) by 10,000 shares on January 8, with a total net reduction of 390,000 shares over the past five trading days and 1,546,000 shares over the past 20 trading days [1] - As of now, southbound funds hold 75,161,000 shares of Hema Medical, which accounts for 6.09% of the company's total issued ordinary shares [1] Group 2 - Hema Medical Holdings Limited, formerly known as Hema Eye Medical Holdings Limited, is primarily engaged in providing medical services through four business segments [2] - The Hong Kong medical business segment focuses on offering ophthalmology, dentistry, and other medical services, as well as selling vision aids [2] - The mainland dental business segment is dedicated to providing dental services in mainland China [2] - The medical consumables sales segment primarily involves selling medical consumables in Hong Kong [2] - The mainland ophthalmology business segment focuses on providing ophthalmology services and selling vision aids in mainland China [2]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Meisi Health (02138.HK) by 39,000 shares on January 8, indicating a trend of net selling over recent trading days [1] - Over the past five trading days, southbound funds have reduced their holdings for five consecutive days, totaling a net reduction of 483,000 shares [1] - In the last twenty trading days, there has been a consistent reduction in holdings by southbound funds, with a cumulative net reduction of 1,185,000 shares [1] Group 2 - As of now, southbound funds hold 19.4 million shares of Meisi Health (02138.HK), which represents 1.7% of the company's total issued ordinary shares [1] - Meisi Health operates primarily as an investment holding company providing medical and healthcare services through three business segments [1] - The medical services segment offers medical and dental services, while the aesthetic medical, beauty, and wellness services segment provides aesthetic medical, traditional beauty, hair care, and wellness services, along with the sale of skincare, health, and beauty products [1]

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Group 1: Shareholding Changes - On November 6, southbound funds reduced their holdings by 58,000 shares, marking a decrease of 0.07% [2]. - Over the past five trading days, there has been a cumulative net reduction of 1,252,000 shares, with reductions occurring on all five days [1][2]. - In the last twenty trading days, the total net reduction reached 3,934,000 shares, with reductions on all twenty days [1]. Group 2: Current Holdings - As of the latest data, southbound funds hold 77,831,000 shares of Hema Medical, which represents 6.19% of the company's total issued ordinary shares [1][2]. Group 3: Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: Hong Kong medical services, mainland dental services, medical consumables sales, and mainland ophthalmic services [2].

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Summary by Sections Southbound Fund Holdings - On October 22, southbound funds reduced their holdings by 72,000 shares, marking a decrease of 0.09% [2]. - Over the past five trading days, there has been a cumulative net reduction of 634,000 shares, with reductions occurring on all five days [1][2]. - In the last 20 trading days, the total net reduction reached 3,286,000 shares, with reductions on all 20 days [1]. Current Holdings - As of the latest data, southbound funds hold a total of 79,449,000 shares of Hema Medical, which represents 6.32% of the company's total issued ordinary shares [1][2]. Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: - The Hong Kong medical division focuses on ophthalmology, dentistry, and other medical services, as well as the sale of vision aids [2]. - The mainland dental division provides dental services in mainland China [2]. - The medical consumables division sells medical consumables in Hong Kong [2]. - The mainland ophthalmology division offers ophthalmic services and sells vision aids in mainland China [2].

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Summary by Sections Southbound Fund Holdings - On October 15, southbound funds reduced their holdings by 88,000 shares, marking a decrease of 0.11% [2]. - Over the past five trading days, there has been a cumulative net reduction of 1,242,000 shares, with reductions occurring on all five days [1][2]. - In the last 20 trading days, the total net reduction reached 3,440,000 shares, with reductions on all 20 days [1]. Current Holdings - As of now, southbound funds hold 80,083,000 shares of Hema Medical, which represents 6.37% of the company's total issued ordinary shares [1]. Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: - The Hong Kong medical division focuses on ophthalmology, dentistry, and other medical services, along with the sale of vision aids [2]. - The mainland dental division provides dental services in mainland China [2]. - The medical consumables sales division operates in Hong Kong [2]. - The mainland ophthalmology division offers ophthalmic services and sells vision aids in mainland China [2].

Core Viewpoint - 盈健医疗 (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to shareholders was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in revenue from general medical services, specialized medical services, and dental services [1] - The gross profit also increased, attributed to the overall revenue growth [1]

Core Viewpoint - 盈健医疗 (01419.HK) reported a revenue of approximately HKD 644 million for the fiscal year 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year increase of about 8.9% [1] - The board proposed a final dividend of HKD 0.03 per share for the fiscal year 2025, up from HKD 0.028 in fiscal year 2024 [1] Revenue and Profit Growth - The company achieved a steady revenue growth despite ongoing adverse economic conditions in Hong Kong, with a revenue increase of approximately 9.1% compared to fiscal year 2024 [1] - The profit attributable to the owners increased by about 8.9% year-on-year, indicating strong financial performance [1] Business Segment Performance - The core business segments maintained balanced growth, with the primary care division showing stable performance driven by network expansion and a strong patient base [1] - The specialty medical division experienced robust revenue growth due to service upgrades and the addition of more specialists, particularly in ophthalmology, pediatric surgery, cardiology, psychiatry, and orthopedics [1] - Despite competitive pressures in the dental segment, overall revenue growth was achieved following the acquisition of Youde Dental in fiscal year 2025 [1]

Core Viewpoint - Yingjian Medical (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in general medical services, specialized medical services, and dental services [1] - Gross profit increased due to the rise in revenue [1]